Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.

Takahiro MaedaHiroaki KanzakiTetsuhiro ChibaJunjie AoKengo KanayamaSusumu MarutaYuko KusakabeTomoko SaitoKazufumi KobayashiSoichiro KiyonoMasato NakamuraSadahisa OgasawaraEiichiro SuzukiYoshihiko OokaShingo NakamotoRyo NakagawaRyosuke MuroyamaTatsuo KandaHitoshi MaruyamaNaoya Kato

Published in: BMC cancer (2019)

Our findings reveal that FGF19 can be a potential novel biomarker for HCC. Although FGF19 is not necessarily a substitute for existing markers, it may help improve the prognosis in HCC patients owing to its resourceful use in various aspects of HCC management and treatment.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
human health
gene expression
genome wide
climate change
replacement therapy